Key statistics
As of last trade WAVE Life Sciences Ltd (1U5:FRA) traded at 5.30, -14.52% below its 52-week high of 6.20, set on Mar 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.30 |
---|---|
High | 5.30 |
Low | 5.30 |
Bid | 5.05 |
Offer | 5.15 |
Previous close | 5.30 |
Average volume | 71.43 |
---|---|
Shares outstanding | 124.74m |
Free float | 104.46m |
P/E (TTM) | -- |
Market cap | 708.51m USD |
EPS (TTM) | -0.5796 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 07:21 BST.
More ▼
Announcements
- Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy
- Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
- Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024
- Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease
- Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
- Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference
- Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
- Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
- Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference
- Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
More ▼